Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases.

[1]  Hong-Kyu Kim,et al.  Association of elevated serum ferritin concentration with insulin resistance and impaired glucose metabolism in Korean men and women. , 2011, Metabolism: clinical and experimental.

[2]  H. Tjalsma,et al.  Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  S. Saab,et al.  Serum ferritin concentration predicts mortality in patients awaiting liver transplantation , 2010, Hepatology.

[4]  L. N. Valenti,et al.  377 BETA-GLOBIN MUTATIONS ARE ASSOCIATED WITH PARENCHYMAL SIDEROSIS AND FIBROSIS SEVERITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE , 2010 .

[5]  L. Valenti,et al.  Hemochromatosis gene (HFE) mutations and cancer risk: Expanding the clinical manifestations of hereditary iron overload , 2010, Hepatology.

[6]  X. Shen,et al.  Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis , 2010, Journal of experimental & clinical cancer research : CR.

[7]  G. Marchesini,et al.  HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. , 2010, Gastroenterology.

[8]  L. Valenti,et al.  Tumorigenesis and Neoplastic Progression Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis , 2010 .

[9]  L. N. Valenti,et al.  Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors , 2010, Hepatology.

[10]  D. Girelli,et al.  Reduced serum hepcidin levels in patients with chronic hepatitis C. , 2009, Journal of hepatology.

[11]  Jianguo Song,et al.  Ferritin heavy chain-mediated iron homeostasis and subsequent increased reactive oxygen species production are essential for epithelial-mesenchymal transition. , 2009, Cancer research.

[12]  G. Cabibbo,et al.  Hyperferritinemia is a risk factor for steatosis in chronic liver disease. , 2009, World journal of gastroenterology.

[13]  M. Torbenson,et al.  Marked Iron in Liver Explants in the Absence of Major Hereditary Hemochromatosis Gene Defects: A Risk Factor for Cardiac Failure , 2009, Transplantation.

[14]  D. Watters,et al.  Ferritin functions as a proinflammatory cytokine via iron‐independent protein kinase C zeta/nuclear factor kappaB–regulated signaling in rat hepatic stellate cells , 2009, Hepatology.

[15]  M. Massari,et al.  Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C , 2009, The American Journal of Gastroenterology.

[16]  P. Micheli,et al.  Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. , 2009, Journal of hepatology.

[17]  L. N. Valenti,et al.  Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations? , 2009, Internal and emergency medicine.

[18]  Y. Takei,et al.  Iron Overload Is Associated with Hepatic Oxidative Damage to DNA in Nonalcoholic Steatohepatitis , 2009, Cancer Epidemiology Biomarkers & Prevention.

[19]  M. Katze,et al.  Down-regulation of hepcidin in porphyria cutanea tarda. , 2008, Blood.

[20]  Y. Takei,et al.  Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. , 2008, Journal of hepatology.

[21]  D. Brenner,et al.  Hepatitis C virus–induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity , 2008, Hepatology.

[22]  D. Swinkels,et al.  Hepcidin in the management of patients with mild non-hemochromatotic iron overload: Fact or fiction? , 2008, Journal of hepatology.

[23]  C. Datz,et al.  Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[24]  M. Melbye,et al.  Cancer as a ferrotoxic disease: are we getting hard stainless evidence? , 2008, Journal of the National Cancer Institute.

[25]  P. Lavori,et al.  Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. , 2008, Journal of the National Cancer Institute.

[26]  M. Muckenthaler.  Fine tuning of hepcidin expression by positive and negative regulators. , 2008, Cell metabolism.

[27]  D. Barisani,et al.  Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload. , 2008, Journal of hepatology.

[28]  L. N. Valenti,et al.  HFE mutations in nonalcoholic fatty liver disease , 2008, Hepatology.

[29]  C. Datz,et al.  Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. , 2008, The American journal of clinical nutrition.

[30]  L. Powell,et al.  Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. , 2008, Blood.

[31]  P. Castellino,et al.  The HFE gene heterozygosis H63D: a cofactor for liver damage in patients with steatohepatitis? Epidemiological and clinical considerations , 2008, Internal medicine journal (Print).

[32]  L. Valenti,et al.  Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. , 2008, The American journal of pathology.

[33]  P. Arosio,et al.  New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. , 2008, Journal of autoimmunity.

[34]  S. Cross,et al.  Overexpression of Cellular Iron Import Proteins Is Associated with Malignant Progression of Esophageal Adenocarcinoma , 2008, Clinical Cancer Research.

[35]  K. Okita,et al.  Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. , 2008, Gastroenterology.

[36]  J. Olynyk,et al.  HCV, iron, and oxidative stress: the new choreography of hepcidin. , 2008, Gastroenterology.

[37]  M. Ziol,et al.  Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. , 2008, Gastroenterology.

[38]  J. Gollan,et al.  Iron‐mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol , 2007, Hepatology.

[39]  A. Pietrangelo.  Hemochromatosis: An endocrine liver disease , 2007, Hepatology.

[40]  L. Cremonesi,et al.  Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. , 2007, Haematologica.

[41]  A. Heim,et al.  Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. , 2007, Human molecular genetics.

[42]  L. N. Valenti,et al.  Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study , 2007, The American Journal of Gastroenterology.

[43]  P. Brissot,et al.  Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. , 2007, Journal of hepatology.

[44]  M. Kaito,et al.  Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C , 2007, Molecular medicine.

[45]  G. Bellomo,et al.  Heterozygous β-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C , 2006, Gut.

[46]  R. Fontana,et al.  Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. , 2006, Gastroenterology.

[47]  D. Richardson,et al.  A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics , 2006, Proceedings of the National Academy of Sciences.

[48]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[49]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[50]  G. Berx,et al.  Modulation of iron transport proteins in human colorectal carcinogenesis , 2006, Gut.

[51]  E. Lander,et al.  Reactive oxygen species have a causal role in multiple forms of insulin resistance , 2006, Nature.

[52]  M. Ziol,et al.  Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. , 2006, Cancer research.

[53]  A. Dalton,et al.  HFE Genotypes in Decompensated Alcoholic Liver Disease: Phenotypic Expression and Comparison with Heavy Drinking and with Normal Controls , 2006, The American Journal of Gastroenterology.

[54]  C. Hellerbrand,et al.  Association between serum ferritin and the insulin resistance syndrome in a representative population. , 2006, European journal of endocrinology.

[55]  M. Kew,et al.  Iron‐free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron , 2006, The Journal of pathology.

[56]  A. Gattoni,et al.  Role of hemochromatosis genes in chronic hepatitis C. , 2006, La Clinica terapeutica.

[57]  C. Day.  From fat to inflammation. , 2006, Gastroenterology.

[58]  D. Purdie,et al.  Steatosis is a cofactor in liver injury in hemochromatosis. , 2005, Gastroenterology.

[59]  C. Camaschella.  Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. , 2005, Blood.

[60]  G. Marchesini,et al.  Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease , 2005, Hepatology.

[61]  D. Girelli,et al.  Prevalence of body iron excess in the metabolic syndrome. , 2005, Diabetes care.

[62]  L. N. Valenti,et al.  Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. , 2005, Blood cells, molecules & diseases.

[63]  B. Bacon,et al.  Duration of Hepatic Iron Exposure Increases the Risk of Significant Fibrosis in Hereditary Hemochromatosis: A New Role for Magnetic Resonance Imaging , 2005, The American Journal of Gastroenterology.

[64]  H. Bonkovsky,et al.  Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  S. Galimberti,et al.  Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. , 2005, American journal of clinical pathology.

[66]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[67]  E. Guallar,et al.  Serum ferritin and risk of the metabolic syndrome in U.S. adults. , 2004, Diabetes care.

[68]  A. Pietrangelo.  Hereditary hemochromatosis--a new look at an old disease. , 2004, The New England journal of medicine.

[69]  G. Marchesini,et al.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.

[70]  L. N. Valenti,et al.  TNFalpha promoter polymorphisms in Italian patients with porphyria cutanea tarda. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[71]  N. Ganne-Carrié,et al.  Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis , 2003, Gut.

[72]  C. Hellerbrand,et al.  HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[73]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[74]  D. Häussinger,et al.  HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. , 2003, Journal of hepatology.

[75]  M. Bronner,et al.  Hepatitis C, iron status, and disease severity: relationship with HFE mutations. , 2003, Gastroenterology.

[76]  J. Fernández-Real,et al.  Cross-talk between iron metabolism and diabetes. , 2002, Diabetes.

[77]  M. Weltman,et al.  HFE mutations, hepatic iron, and fibrosis: Ethnic‐specific association of NASH with C282Y but not with fibrotic severity , 2002, Hepatology.

[78]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[79]  A. Nicolucci,et al.  Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. , 2002, Blood.

[80]  F. Facchini,et al.  Effect of Iron Depletion on Cardiovascular Risk Factors , 2002, Annals of the New York Academy of Sciences.

[81]  F. Aucella,et al.  [Thalassaemia minor: national survey of uraemic patients under substitutive treatment]. , 2002, Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.

[82]  M. Massari,et al.  Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study , 2002, American Journal of Gastroenterology.

[83]  L. Rodrigo,et al.  HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. , 2002 .

[84]  R. Stoohs,et al.  Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[85]  R. N. Macsween,et al.  The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C , 2002, Gut.

[86]  J. Yewdell,et al.  Human Cytomegalovirus Protein US2 Interferes with the Expression of Human HFE, a Nonclassical Class I Major Histocompatibility Complex Molecule That Regulates Iron Homeostasis , 2001, Journal of Virology.

[87]  E. Taioli,et al.  Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. , 2001, Journal of hepatology.

[88]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[89]  M. Mattioli,et al.  Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron‐related chronic liver disease , 2001, Hepatology.

[90]  P. Brissot,et al.  Letters to the Editor: Non-alcoholic steatohepatitis with iron: part of insulin resistanceassociated hepatic iron overload? , 2000 .

[91]  J. L. Le Gall,et al.  Insulin resistance-associated hepatic iron overload. , 1999, Gastroenterology.

[92]  Kou-Juey Wu,et al.  Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.

[93]  D. Gorson.  Reduction of Macroalbuminuria With Pentoxifylline in Diabetic Nephropathy: Report of three cases , 1998, Diabetes Care.

[94]  F. Facchini.  Effect of Phlebotomy on Plasma Glucose and Insulin Concentrations , 1998, Diabetes Care.

[95]  J. Grove,et al.  Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease , 1998, Gut.

[96]  J. Grove,et al.  Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C , 1998, Hepatology.

[97]  M. Mattioli,et al.  High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda , 1998, Hepatology.

[98]  M. Mattioli,et al.  High prevalence of hepatitis C virus type 1b in Italian patients with Porphyria cutanea tarda. , 1997, Italian journal of gastroenterology and hepatology.

[99]  P. Brissot,et al.  Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver , 1995, Hepatology.

[100]  S. Fargion,et al.  Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis , 1994, Hepatology.

[101]  B. Cesana,et al.  Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis , 1992, Hepatology.